The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results

EuroInterv.2008;4:71-76.

1. HELIOS Heart Center Siegburg, Siegburg, Germany; 2. Cardiovascular Center Frankfurt, Frankfurt, Germany; 3. Barmherzige Brueder-Krankenhaus Trier, Trier, Germany; 4. University of Florida Core Imaging Laboratories, Jacksonville, Florida, USA; 5. Center

Aims: The Custom NX® 36 Drug Eluting Stent (DES) System is designed to treat coronary lesions via in situ stent length customisation. The stent evaluated in th

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT)